In the original publication [1], there was a mistake in Figure 7. Results figures from Figure 6D,H have been inserted in Figure 7. The corrected Figure 7 appears below.
Figure 7.
Mito−TIPTP alleviates chronic DSS−induced colitis in mice. (A) Schematic of the chronic colitis model treated 2.5% DSS with Mito−TIPTP (50 ng/kg). (B) The survival of mice was monitored for 9 weeks; mortality was measured for n = 15 mice per group. (C) Weight loss of vehicle or Mito−TIPTP in mice (n = 15). (D) Image (up) and length (down) of colon in 2.5% DSS−induced chronic colitis mice with vehicle or Mito−TIPTP. (E) Representative imaging of H&E staining of the colon (left) (n = 8). Histopathology scores were obtained from H&E staining were determined in 2.5% DSS−induced chronic colitis mice with vehicle or Mito−TIPTP. Scale bar, 100 μm. Statistical significance was determined by Student’s t−test with Bonferroni adjustment (*** p < 0.001) compared with vehicle.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Reference
- 1.Kim J.-S., Kim Y.-R., Jang S., Wang S.G., Cho E., Mun S.-J., Jeon H.-I., Kim H.-K., Min S.-J., Yang C.-S. Mito-TIPTP Increases Mitochondrial Function by Repressing the Rubicon-p22phox Interaction in Colitis-Induced Mice. Antioxidants. 2021;10:1954. doi: 10.3390/antiox10121954. [DOI] [PMC free article] [PubMed] [Google Scholar]